01—Abstract
Summary
Summary of the 8-K filed April 22, 2026. Cited figures are marked; the original filing is the authoritative source.
Medpace Holdings, Inc. reported financial results for the three months ended March 31, 2026, in a press release furnished as Exhibit 99.1 to this Form 8-K filed April 22, 2026.
Revenue rose 26.5% to $706.6 milliona from $558.6 million a year earlier. Net new business awards were $618.4 million, up 23.7% from $500.0 million, for a net book-to-bill ratio of 0.88x. Backlog as of March 31, 2026 was $2,929.2 million, up 2.9% from $2,846.0 million.
GAAP net income was $123.9 millionb, or $4.28 per diluted share, compared with $114.6 million, or $3.67 per diluted share, in the prior-year quarter. EBITDA was $149.4 million, up 25.9%, with an EBITDA margin of 21.1%. For full-year 2026, the company forecasts revenue of $2.755 billion to $2.855 billion, GAAP net income of $487.0 million to $511.0 million, EBITDA of $605.0 million to $635.0 million, and diluted EPS of $16.68 to $17.50.
The guidance assumes a 19.0% to 20.0% tax rate and 29.2 million diluted weighted average shares, and excludes any share repurchases after March 31, 2026. Cash and cash equivalents were $652.7 millionc at March 31, 2026, and operating cash flow for the quarter was $151.8 million.
The filing also discloses that President Jesse Geiger notified the company on April 21, 2026, of his intent to resign and retire effective May 31, 2026, and that the departure is not the result of any disagreement with the company. Chief Executive Officer August Troendle will reassume the role of President until a successor is appointed.
02—Key points
Key Highlights
- Revenue of $706.6 million, up 26.5% year over year; constant-currency revenue growth of 25.8%.
- Net new business awards of $618.4 million, up 23.7%, producing a net book-to-bill ratio of 0.88x; backlog of $2,929.2 million at March 31, 2026.
- GAAP net income of $123.9 million, or $4.28 per diluted share, versus $3.67 per diluted share a year earlier; net income margin of 17.5% compared with 20.5%.
- EBITDA of $149.4 million, up 25.9%, with an EBITDA margin of 21.1%.
- Full-year 2026 guidance: revenue of $2.755 billion to $2.855 billion and diluted EPS of $16.68 to $17.50.
- Cash and cash equivalents of $652.7 million at March 31, 2026, up from $497.0 million at December 31, 2025; operating cash flow of $151.8 million in the quarter.
- President Jesse Geiger will retire effective May 31, 2026; CEO August Troendle will reassume the President role until a successor is appointed.
03—Questions
Frequently Asked Questions
How did Medpace perform in the first quarter of 2026?
Revenue grew 26.5% to $706.6 million, GAAP net income was $123.9 million ($4.28 per diluted share), and EBITDA rose 25.9% to $149.4 million. Net income margin fell to 17.5% from 20.5% in the prior-year quarter, while EBITDA margin was 21.1%.
What is the company's outlook for 2026?
Medpace forecasts 2026 revenue of $2.755 billion to $2.855 billion, GAAP net income of $487.0 million to $511.0 million, EBITDA of $605.0 million to $635.0 million, and diluted EPS of $16.68 to $17.50. The guidance assumes a 19.0% to 20.0% tax rate, $27.5 million of interest income, and 29.2 million diluted weighted average shares, and excludes any share repurchases after March 31, 2026.
How strong are new business awards and backlog?
Net new business awards were $618.4 million in the quarter, up 23.7%, giving a net book-to-bill ratio of 0.88x. Backlog at March 31, 2026 was $2,929.2 million, up 2.9% from $2,846.0 million a year earlier.
Why is the President leaving, and who will take over?
Jesse Geiger notified the company on April 21, 2026, of his intent to resign as President and retire effective May 31, 2026. The filing states the departure is not the result of any disagreement regarding operations, policies, or practices. CEO August Troendle will reassume the President role until the company appoints a successor.
What is the company's cash position?
Cash and cash equivalents were $652.7 million at March 31, 2026, compared with $497.0 million at December 31, 2025. Operating activities generated $151.8 million in cash during the first quarter of 2026.
04—Continue